Ardelyx, INC

Ardelyx, Inc. stockholders approved an amendment to its equity incentive plan and elected Class III directors at the 2026 Annual Meeting.

Ardelyx announced robust 2025 financial results, driven by significant IBSRELA revenue growth and progress in its clinical pipeline, while projecting continued expansion into 2026.

Ardelyx announced preliminary unaudited U.S. net product sales of IBSRELA and XPHOZAH, alongside its cash position for Q4 and full-year 2025.

Ardelyx, Inc. announced the resignations of its Chief Legal and Administrative Officer and Chief Medical Officer, both effective December 31, 2025.

Ardelyx, Inc. reported strong third-quarter 2025 financial results, with total product revenue increasing 15% year-over-year, driven by a 92% surge in IBSRELA revenue and a new pipeline program.

Ardelyx, Inc. announced the appointment of Sue Hohenleitner, a former Johnson & Johnson executive, as its new Chief Financial Officer, effective November 4, 2025.

Ardelyx reports increased total revenue driven by strong IBSRELA sales and milestone payments, but faces a larger net loss and significant XPHOZAH sales decline due to Medicare Part D changes.

Ardelyx reports strong IBSRELA sales growth and new financing, but faces increased net losses and challenges for XPHOZAH due to Medicare policy changes.

Ardelyx's Q1 2025 revenue surged, fueled by increased sales of IBSRELA and XPHOZAH, alongside a licensing milestone achievement.

Ardelyx's Q3 2024 results show significant revenue growth driven by product sales, while the company addresses regulatory hurdles regarding XPHOZAH's inclusion in the ESRD PPS.

Ardelyx's Q2 2024 results show significant revenue growth, primarily driven by increased sales of IBSRELA and the launch of XPHOZAH.

Ardelyx's Q1 2024 financial results show significant revenue growth, primarily driven by increased sales of IBSRELA and the launch of XPHOZAH.

Ardelyx reports significant revenue growth driven by IBSRELA and XPHOZAH sales, while addressing challenges related to Medicare Part D coverage changes for XPHOZAH.

Ardelyx's 2023 10-K filing details a year of commercial expansion with IBSRELA and the launch of XPHOZAH, alongside ongoing financial challenges and strategic developments.

Michael Raab, President & CEO and a Director of Ardelyx, Inc., sold 41,668 shares of common stock on July 15, 2026 for $5.06 per share.

Merdad Parsey, a Director at Ardelyx, Inc., reported transactions involving common stock and stock options on June 16, 2026.

Ardelyx, Inc. Director Richard J. Rodgers acquired 26,455 shares of common stock and was granted an option to purchase 39,715 shares.

Ardelyx, Inc. director David Mott acquired shares and stock options under the company's compensation program on June 16, 2026.

Onaiza Cadoret-Manier, a Director at Ardelyx, Inc., has reported transactions involving restricted stock units and stock options.

Ardelyx, Inc. Director Muna Bhanji has reported transactions involving restricted stock units and stock options, as filed with the SEC.

Ardelyx is asking stockholders to approve an amendment to its equity incentive plan, increasing the share reserve by 10 million to attract and retain talent.

Ardelyx issues a supplement to its proxy statement clarifying details regarding the proposed amendment and restatement of its 2014 Equity Incentive Award Plan.

Ardelyx, Inc. announces its 2024 Annual Meeting of Stockholders to be held on June 14, 2024, featuring proposals including director elections and amendments to equity incentive plans.

Janus Henderson Group plc has filed a Schedule 13G, reporting beneficial ownership of 3.4% of Ardelyx, Inc. common stock as of March 31, 2026.

State Street Corporation has reported a beneficial ownership of 5.5% of Ardaelyx Inc.'s common stock as of March 31, 2026.

Several entities affiliated with Millennium Management have collectively reported beneficial ownership of 7.4% of Ardelyx, Inc.'s common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting zero beneficial ownership in Ardelyx Inc. common stock following an internal realignment.

The Vanguard Group reported a 7.81% beneficial ownership in Ardelyx Inc, totaling 18,979,483 common shares, following an internal realignment.

Millennium Management LLC and affiliated entities have reported beneficial ownership of 5.4% of Ardelyx, Inc.'s common stock.